Recommends obtaining a lipid profile at diagnosis to assess for dyslipidemia in adults with growth hormone deficiency. Trigger phrases include "New diagnosis of GHD", "Initial lipid assessment in growth hormone disorder", and "Baseline lipid profile in hypopituitarism".
Installs into .claude/skills of the current project.
Are you the author of Endo Obtain Lipid Profile Diagnosis Growth Hormone Deficiency?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-endo-obtain-lipid-profile-diagnosis-growth-hormone)
---
name: endo-obtain-lipid-profile-diagnosis-growth-hormone-deficiency
description: Recommends obtaining a lipid profile at diagnosis to assess for dyslipidemia in adults with growth hormone deficiency. Trigger phrases include "New diagnosis of GHD", "Initial lipid assessment in growth hormone disorder", and "Baseline lipid profile in hypopituitarism".
---
# Obtain lipid profile at diagnosis to assess for dyslipidemia in growth hormone deficiency
## STEP 1 — Gather Information
Confirm adult growth hormone deficiency (GHD) diagnosis via low IGF-1 and/or subnormal GH stimulation test; document pituitary history or hypopituitarism if present.
**Action:** Proceed to lipid profile if GHD is confirmed.
## STEP 2 — Rule In / Rule Out
Is the patient diagnosed with adult GHD?
- Yes: Continue to lipid assessment.
- No: Stop; lipid profile not indicated per this guideline.
**Action:** If yes, obtain fasting or non-fasting lipid panel.
## STEP 3 — Classify or Stratify
Interpret lipid panel: total cholesterol, LDL-C, HDL-C, triglycerides.
- Normal: LDL-C <100 mg/dL, HDL-C ≥40 mg/dL (men) / ≥50 mg/dL (women), TG <150 mg/dL.
- Abnormal: Any value outside normal ranges.
**Action:** Classify as normal or dyslipidemia present.
## STEP 4 — Decide
If dyslipidemia is identified, initiate cardiovascular risk assessment and consider lipid-lowering therapy per endocrine disorder guidelines; if normal, repeat lipid profile annually or as clinically indicated.
**Action:** Treat or monitor accordingly.
## Clinical Guardrails / Mimics / Pitfalls
Do not use GH replacement solely to lower LDL-C to reduce cardiovascular risk; ensure lipid assessment is not delayed in hypopituitarism; non-fasting panels are acceptable for initial screening but repeat fasting if TG elevated or genetic dyslipidemia suspected.
## Concrete Clinical Example
A 45-year-old woman with newly diagnosed GHD (low IGF-1, failed GH stimulation) undergoes lipid panel: LDL-C 130 mg/dL, HDL-C 45 mg/dL, TG 180 mg/dL. Dyslipidemia identified; statin therapy initiated after risk discussion.
**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, DOI:10.1210/clinem/dgaa674
